Matches in SemOpenAlex for { <https://semopenalex.org/work/W2784390474> ?p ?o ?g. }
Showing items 1 to 83 of
83
with 100 items per page.
- W2784390474 endingPage "40" @default.
- W2784390474 startingPage "29" @default.
- W2784390474 abstract "One way to improve the results of treatment of patients with locally advanced triple-negative breast cancer (TNBC) is to find the most effective neoadjuvant chemotherapy regimen. It has been shown that patients (pts) with TNBC with pathological complete regression (pCR) after neoadjuvant chemotherapy have better survival. The aim of the study was to evaluate the efficacy and toxicity of induction chemotherapy regimen, including 2 consequent chemotherapy regimens: рaclitaxel 60 mg/m 2 IV weekly plus сarboplatinum AUC2 IV weekly for 9 weeks, then doxorubicin 25 mg/m 2 IV weekly plus cyclophosphamide 50 mg per os q. i. d. plus capecitabine 500 mg t. i. d for 9 weeks. The study included 45 patients with TNBC, stages IIIA, IIIB, IIIC. Overall response rate was 40/45 (88,9%) with 7/45 (15,6%) of complete responses and 33/45 (73,3%) of partial responses. Forty-four patients underwent surgery. Twenty seven patients (61,4%) achieved pCR. Three-year disease-free survival was 71% and overall survival was 81%. The most common types of toxicity were neutropenia (40% grade 3–4), mucositis (55% grade 1–3) and hand-foot syndrome (65% grade 1–3). Despite relatively high toxicity this alternating multicomponent induction chemotherapy regimen had high efficacy. More than half of patients (61.4%) achieved pCR." @default.
- W2784390474 created "2018-02-02" @default.
- W2784390474 creator A5000721617 @default.
- W2784390474 creator A5028263106 @default.
- W2784390474 creator A5034196481 @default.
- W2784390474 creator A5034246940 @default.
- W2784390474 creator A5045467858 @default.
- W2784390474 creator A5070230769 @default.
- W2784390474 creator A5018894308 @default.
- W2784390474 date "2017-01-01" @default.
- W2784390474 modified "2023-09-25" @default.
- W2784390474 title "EVALUATION OF EFFICACY AND TOXICITY OF NEOADJUVANT ALTERNATING CHEMOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED TRIPLE NEGATIVE BREAST CANCER" @default.
- W2784390474 doi "https://doi.org/10.18027/2224-5057-2017-7-4-29-40" @default.
- W2784390474 hasPublicationYear "2017" @default.
- W2784390474 type Work @default.
- W2784390474 sameAs 2784390474 @default.
- W2784390474 citedByCount "0" @default.
- W2784390474 crossrefType "journal-article" @default.
- W2784390474 hasAuthorship W2784390474A5000721617 @default.
- W2784390474 hasAuthorship W2784390474A5018894308 @default.
- W2784390474 hasAuthorship W2784390474A5028263106 @default.
- W2784390474 hasAuthorship W2784390474A5034196481 @default.
- W2784390474 hasAuthorship W2784390474A5034246940 @default.
- W2784390474 hasAuthorship W2784390474A5045467858 @default.
- W2784390474 hasAuthorship W2784390474A5070230769 @default.
- W2784390474 hasBestOaLocation W27843904741 @default.
- W2784390474 hasConcept C121608353 @default.
- W2784390474 hasConcept C126322002 @default.
- W2784390474 hasConcept C141071460 @default.
- W2784390474 hasConcept C143998085 @default.
- W2784390474 hasConcept C2776611710 @default.
- W2784390474 hasConcept C2776694085 @default.
- W2784390474 hasConcept C2776755627 @default.
- W2784390474 hasConcept C2777063308 @default.
- W2784390474 hasConcept C2777909004 @default.
- W2784390474 hasConcept C2778292576 @default.
- W2784390474 hasConcept C2778496288 @default.
- W2784390474 hasConcept C2780110267 @default.
- W2784390474 hasConcept C2781413609 @default.
- W2784390474 hasConcept C29730261 @default.
- W2784390474 hasConcept C526805850 @default.
- W2784390474 hasConcept C530470458 @default.
- W2784390474 hasConcept C71924100 @default.
- W2784390474 hasConcept C90924648 @default.
- W2784390474 hasConceptScore W2784390474C121608353 @default.
- W2784390474 hasConceptScore W2784390474C126322002 @default.
- W2784390474 hasConceptScore W2784390474C141071460 @default.
- W2784390474 hasConceptScore W2784390474C143998085 @default.
- W2784390474 hasConceptScore W2784390474C2776611710 @default.
- W2784390474 hasConceptScore W2784390474C2776694085 @default.
- W2784390474 hasConceptScore W2784390474C2776755627 @default.
- W2784390474 hasConceptScore W2784390474C2777063308 @default.
- W2784390474 hasConceptScore W2784390474C2777909004 @default.
- W2784390474 hasConceptScore W2784390474C2778292576 @default.
- W2784390474 hasConceptScore W2784390474C2778496288 @default.
- W2784390474 hasConceptScore W2784390474C2780110267 @default.
- W2784390474 hasConceptScore W2784390474C2781413609 @default.
- W2784390474 hasConceptScore W2784390474C29730261 @default.
- W2784390474 hasConceptScore W2784390474C526805850 @default.
- W2784390474 hasConceptScore W2784390474C530470458 @default.
- W2784390474 hasConceptScore W2784390474C71924100 @default.
- W2784390474 hasConceptScore W2784390474C90924648 @default.
- W2784390474 hasIssue "4" @default.
- W2784390474 hasLocation W27843904741 @default.
- W2784390474 hasOpenAccess W2784390474 @default.
- W2784390474 hasPrimaryLocation W27843904741 @default.
- W2784390474 hasRelatedWork W1255356622 @default.
- W2784390474 hasRelatedWork W2024219304 @default.
- W2784390474 hasRelatedWork W2358701816 @default.
- W2784390474 hasRelatedWork W2367105124 @default.
- W2784390474 hasRelatedWork W2388730008 @default.
- W2784390474 hasRelatedWork W2534174115 @default.
- W2784390474 hasRelatedWork W2784390474 @default.
- W2784390474 hasRelatedWork W3089077900 @default.
- W2784390474 hasRelatedWork W3092055942 @default.
- W2784390474 hasRelatedWork W3092178973 @default.
- W2784390474 hasVolume "7" @default.
- W2784390474 isParatext "false" @default.
- W2784390474 isRetracted "false" @default.
- W2784390474 magId "2784390474" @default.
- W2784390474 workType "article" @default.